Raquel Briviesca-Laza
Majadahonda, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 04, 2021
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial.
Journal: Journal for immunotherapy of cancer
Published: July 29, 2021
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.
Journal: Clinical and translational medicine
Published: April 13, 2021
KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Journal: ESMO open
Published: April 06, 2021
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 31, 2021
The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy.
Journal: Biomedicines
Published: February 28, 2021
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
Journal: Translational lung cancer research
Published: July 18, 2020
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: May 14, 2020
Corrigendum: Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Journal: Frontiers in immunology
Published: January 07, 2020
Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Journal: Clinical chemistry and laboratory medicine
Published: July 21, 2019
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition.
Journal: Free radical biology & medicine
Published: September 11, 2018
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling.
Journal: Free radical biology & medicine
Published: August 21, 2018
Last Updated: 09/26/2026